Fuzhou Infectious Diseases Hospital Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2009
NCT00813267
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Fuzhou Infectious Diseases Hospital | Jianming Tan

Active Ingredients

Drugs in Phase 1 Trials (2)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

autologous mesenchymal stem cells (1 trial)

Drugs in Other Trials (1)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteochondritis (Phase 1)

Osteonecrosis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3